LATEST PRESS RELEASE
Amorfix Announces The Development Of Antibodies That Bind to Misfolded Fas Receptor Protein As A Potential Treatment For Cancer
May 16, 2012
Amorfix has developed antibodies that selectively target and bind to misfolded Fas receptor protein expressed on the cell surface of cancer cells.
Download PDFAmorfix Closes Private Placement Offering
May 14, 2012
Amorfix has closed a non-brokered private placement (the Offering) pursuant to which a total of 2,585,000 units (Units) were issued at a price of $0.40 per unit for gross proceeds of $1,034,000.
Download PDFAmorfix Announces Private Placement
May 08, 2012
Amorfix intends to complete, subject to regulatory approval, a non-brokered private placement of up to 2,500,000 units (Units) at a price of $0.40 per Unit, for gross proceeds of $1,000,000, of which commitments to subscribe for 2,200,000 units have been received.
Download PDFEVENTS
The Alzheimer's Association 2011 International Conference on Alzheimer's Disease
July 16 -21, 2011 : Paris, France
Development of An Ultra Sensitive Assay for Detection of Aggregated Beta Amyloid in Human CSF
Click here to visit site10th International Conference on Alzheimer's and Parkinson's Diseases
March 9-13, 2011: Barcelona, Spain
Detection of β-Amyloid Aggregates in CSF From Transgenic Animal Models of Alzheimer's Disease Using the Amorfix Aggregated Abeta Assay (A4)
Click here to visit site
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease.
Amorfix is a pioneer in the ability to identify unique regions that are buried in normal proteins, and exposed to antibodies when proteins are aberrantly folded. These unique regions are designated Disease Specific Epitopes™ (DSE), which can be exploited by Amorfix to develop highly specific diagnostic tools, as well as targets for therapeutics of protein misfolding diseases.
Click here for information on the Amorfix Aggregated Aβ Assay (A4) Service.